BioInvent International AB (publ) (0H22.IL)

38,00 -0,25 (-0,65%) Al cierre: 03:57PM BST

BioInvent International AB (publ)

The Gamma Building
Ideongatan 1
Lund 223 70
Sweden
46 4 62 86 85 50
https://www.bioinvent.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 103

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Martin Welschof Ph.D.	Pres & CEO	5,06M	N/A	1961
Mr. Stefan Ericsson M.B.A.	Chief Financial Officer	N/A	N/A	1963
Ms. Marie Moores M.Sc., R.G.N.	Chief Operating Officer	N/A	N/A	N/A
Mr. Kristoffer Rudenholm Hansson	Sr. VP of Technical Operations	N/A	N/A	1974
Mr. Björn Frendéus	Chief Scientific Officer	N/A	N/A	1973
Ms. Cecilia Hofvander	Sr. Director of Investor Relations	N/A	N/A	1967
Dr. Andres McAllister	Chief Medical Officer	N/A	N/A	1956
Ms. Ingrid Teige	Head of Preclinical Research	N/A	N/A	N/A
Ms. Sylvie Ryckebusch	Chief Bus. Officer	N/A	N/A	N/A
Dr. Ingunn Munch Lindvig	Sr. VP of Regulatory Affairs	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en SEK.

Descripción

BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 for solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a partnership and collaboration with Transgene to co-develop BT-001 multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BT-001 in combination with Keytruda, and in BI-1808. BioInvent International AB (publ) was incorporated in 1996 and is based in Lund, Sweden.

Gobierno corporativo

El ISS Governance QualityScore de BioInvent International AB (publ), a día 1 de octubre de 2023, es 5. Las puntuaciones base son Auditoría: 9; Tablero: 2; Derechos de los accionistas: 1; Compensación: 9.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.